Skip Navigation

Lotus Reported Unaudited November Consolidated Revenues of NT$1,135 million, representing 25% MoM Growth and 6% YoY Growth

08 December 2023

Taipei, Taiwan, December 8, 2023 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taipei, Taiwan, announces its unaudited consolidated revenues for November 2023. The company recorded a consolidated revenues reaching NT$1,135 million for the month, reflecting a 25% month-over-month (MoM) growth and a solid 6% year-over-year (YoY) increase.

For the cumulative 11 months concluding in November 2023, Lotus Pharmaceutical's consolidated revenue amounted to NT$15.59 billion, showcasing an impressive 16.6% growth compared to the same period in the previous year. Notably, the company's Asian operations experienced robust growth, contributing NT$8.2 billion in revenue, reflecting a remarkable 22% increase. Simultaneously, the export segment saw a 12% growth from NT$6.5 billion in 2022 to NT$7.3 billion in 2023. This balanced growth demonstrates the effective diversification of revenue sources, with both Asian and export businesses contributing approximately 50% each to the overall revenue of the Group.

In November, Lotus Pharmaceutical witnessed an 18% growth in Asian revenue, primarily driven by robust performances in Taiwan and Korea. The company continued its strategic expansion into Southeast Asian (SEA) markets, launching Enzalutamide soft gel as the first generic in the Philippines. This move follows the successful introduction of the same product, also as the first generic, in Malaysia in October. Enzalutamide, a generic of Xtandi®, is indicated for prostate cancer and reported a global brand revenue of approximately USD 145 million according to IQVIA data.

The export revenue for November exhibited an 84% increase compared to the previous month. However, it represents a 10% decrease compared to the same period last year. This variance was attributed to the timing of product deliveries in the U.S., offset by a substantial increase in revenue from exports to markets outside of the U.S.

Lotus Pharmaceutical remains committed to its strategy to transform the company a local Taiwanese generic pharmaceutical player into a global platform with a diverse product portfolio encompassing generic drugs, branded drugs, NCEs, and 505(b)(2) products. The company continues to enhance the accessibility of medications for patients worldwide.

About Lotus

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.


 Media Enquiries:

Susan Liao, IR/PR Director

+886 2 2700 5908